Portola Pharmaceuticals, Inc. Follow-On Offering
Davis Polk advised the joint book-running managers and the lead manager in connection with a $258.8 million public offering of common stock by Portola Pharmaceuticals, Inc. The common stock…
Experience
To find Davis Polk deals and cases of particular interest, select filters based on practice, industry, region, lawyer and keyword.
Filters
Stemline Therapeutics, Inc. Common Stock Offering
Davis Polk advised the underwriters in connection with the SEC-registered offering of 5,750,000 shares of common stock of Stemline Therapeutics, Inc. for total gross proceeds of…
Allakos Inc. $402 Million Follow-On Public Offering
Davis Polk advised the joint book-running managers and representatives of the underwriters in connection with the follow-on offering of 5,227,272 shares of common stock of Allakos Inc. for…
PTC Therapeutics, Inc. $125 Million SEC-Registered At-The-Market Offering
Davis Polk advised the sales agents in connection with an SEC-registered at-the-market offering by PTC Therapeutics, Inc. of its shares of common stock for up to an aggregate amount of $125…
Oryzon Genomics’s Private Placement of Ordinary Shares
Davis Polk advised Oryzon Genomics, S.A. on its €20 million private placement of its ordinary shares pursuant to a capital increase. The offering consisted of a private placement to…
Seattle Genetics, Inc. $575 Million Equity Offering
Davis Polk advised the joint book-running managers and representatives of the underwriters in connection with an SEC-registered offering of common stock by Seattle Genetics, Inc. for gross…
Atara Biotherapeutics, Inc. Common Stock and Pre-Funded Warrants Offering
Davis Polk advised the joint book-running managers and representatives of the several underwriters in connection with a $150 million SEC-registered common stock and pre-funded warrants…
Forty Seven, Inc. $86 Million Common Stock Offering
Davis Polk advised the joint book-running managers and representatives of the several underwriters in connection with an $86.25 million public offering of common stock of Forty Seven, …
Hutchison China Meditech Limited $282 Million Secondary Offering
Davis Polk advised the underwriter in connection with a secondary offering of 12,000,000 American Depositary Shares of Hutchison China Meditech Limited (“Chi-Med”), each representing five…
Medtronic Global Holdings S.C.A. €5 Billion Notes Offering
Davis Polk advised the representatives of the several underwriters in connection with an SEC-registered offering of €5 billion aggregate principal amount of notes by Medtronic Global…